Validation of a new assay that uses 2 monoclonal antibodies to measure intact and fragmented plasma CgA levels Abstract #152

Introduction: Plasma chromogranin A (CgA) levels are elevated in a variety of neuroendocrine tumors (NETs) and are used to aid in diagnosis, prognosis, and monitoring of treatment effects in NETs patients. We evaluated a newer sandwich ELISA assay (Cisbio US, Bedford, MA, USA) that utilizes two monoclonal antibodies that bind to the mid-region of the CgA protein and allow measurement of intact and fragmented circulating CgA. The results from the assay validation indicative of its overall robustness in terms of sensitivity, specificity, reproducibility, and stability are presented here.
Aim(s): To validate the CgA ELISA (Cisbio) assay according to the American Association of Pharmaceutical Sciences Ligand Binding Assay Bioanalytical Focus group guidelines and investigate its utility as a tool for use in the clinic.
Materials and methods: Commercial CgA ELISA kit (CisBio, MA) was used according to the manufacturer’s instructions. The sensitivity and dynamic range of the assay were established by measuring the recovery of recombinant CgA spiked into human plasma. Healthy donor and pancreatic NET patient plasma were used to assess the specificity, stability, intraday, and interday variability of the assay.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Monica Motwani

To read results and conclusion, please login ...

Further abstracts you may be interested in

#281 Biochemical Markers in Diagnosis and Monitoring of Neuroendocrine Tumors
Introduction: The biochemical diagnosis and monitoring of neuroendocrine tumors is very important in the clinical management of patients.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Nina V. Lyubimova
#341 Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) v. Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Results
Introduction: In previous phase II studies of EVE in patients with pNET, those with elevated baseline Chromogranin A (eCgA) and neuron-specific enolase (eNSE) levels experienced shorter PFS.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Kjell Oberg
Authors: Oberg K, Anthony L, Sideris L, Chen L T, ...
#727 Serum Levels of Chromogranin A Were Not Elevated in Patients with Insulinomas
Introduction: According to ENETS and NANETS Consensus Guidelines, Chromogranin A (CgA) is the most practical and useful serum tumor marker in NET patients (pts), including pancreatic NETs. Many studies suggested that test of blood CgA should be mandatory for NET diagnosis.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. X-W Qiao
Authors: Qiao X W, Qiu L, Liu B, Song Y L, ...
#804 The Plasma Chromogranin A Level Predicts Survival and Tumor Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Introduction: The plasma chromogranin A (CgA) level is a reliable biomarker for identifying patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: M.D. Tsann-Long Hwang
Authors: Chou W C, Chen J S, Hsu J T, Chen T C, ...
#809 Serum Chromogranin A is a Predictor for Liver Metastatic Tumor Burden and Therapeutic Response in Advanced Non-Functional Pancreatic Neuroendocrine Tumors
Introduction: The relationship between CgA level and liver metastatic (LM) tumor burden as well as therapeutic response is not well-established.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: M.D. Xu Han
Authors: Zhang C, Han X, Tang M, Ji Y, ...
Keywords: CgA NF-PNETs LM